Advanced in Ewing Sarcoma

Dr. Mark A. Ranalli

Pediatric Hematology Oncology

536 S Trimble Rd,

Mansfield, OH

Advanced in Ewing Sarcoma

536 S Trimble Rd,

Mansfield, OH

OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mark Ranalli is a Pediatric Hematologist Oncology provider in Mansfield, Ohio. Dr. Ranalli is rated as an Advanced provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Rhabdoid Tumor, Pancreaticoduodenectomy, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 37 peer reviewed articles and participating in 77 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 11 clinical trials in the study of Ewing Sarcoma.

Specialties

Pediatric Hematology Oncology

Licenses

Pediatrics in OH

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Accepted insurance plans:

Anthem

CareSource

Humana

HMO
INDEMNITY
POS
PPO

Managed Medicaid

OTHER MANAGED MEDICAID

McLaren Health

Medical Health

Medical Mutual

UnitedHealthcare

Wellcare

EPO
HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
MEDICARE-MEDICAID PLAN
OTHER MEDICARE
OTHER MEDICARE PART D

View 4 Less Insurance Carriers -

Locations

536 S Trimble Rd, Mansfield, OH 44906

Call: 614-722-6200

Other Locations

700 Childrens Dr, Columbus, OH 43205

Call: 614-722-3552

4439 State Route 159, Chillicothe, OH 45601

Call: 614-722-2000

7853 Pacer Dr, Delaware, OH 43015

Call: 614-722-2555

2213 Cherry St, Toledo, OH 43608

Call: 567-290-6543

5665 Venture Dr, Dublin, OH 43017

Call: 614-722-2000

500 W Market St, Tiffin, OH 44883

Call: 419-251-8210

6435 E Broad St, Columbus, OH 43213

Call: 614-722-2000

740 Adair Ave, Zanesville, OH 43701

Call: 614-722-2000

Additional Areas of Focus

Dr. Ranalli has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

77 Clinical Trials

A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor

Enrollment Status: Active_not_recruiting

Publish Date: December 08, 2025

Intervention Type: Drug

Study Drugs: Ramucirumab, Cyclophosphamide, Vinorelbine

Study Phase: Phase 1/Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tipifarnib in Patients With Tumors Harboring HRAS Genomic Alterations

Enrollment Status: Active_not_recruiting

Publish Date: December 04, 2025

Intervention Type: Drug

Study Drug: Tipifarnib

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene Alterations

Enrollment Status: Active_not_recruiting

Publish Date: December 04, 2025

Intervention Type: Procedure, Drug

Study Drug: Selpercatinib

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients With Tumors Harboring Actionable NTRK Fusions

Enrollment Status: Active_not_recruiting

Publish Date: December 03, 2025

Intervention Type: Procedure, Drug

Study Drugs: Larotrectinib, Larotrectinib Sulfate

Study Phase: Phase 2

A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups

Enrollment Status: Active_not_recruiting

Publish Date: December 03, 2025

Intervention Type: Drug, Biological

Study Drugs: Axitinib, Nivolumab

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients With Tumors Harboring Activating MAPK Pathway Mutations

Enrollment Status: Active_not_recruiting

Publish Date: December 03, 2025

Intervention Type: Other, Drug

Study Drug: Ulixertinib

Study Phase: Phase 2

Larotrectinib (LOXO-101, NSC# 788607) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias

Enrollment Status: Active_not_recruiting

Publish Date: December 02, 2025

Intervention Type: Drug

Study Drug: Larotrectinib Sulfate

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Erdafitinib in Patients With Tumors Harboring FGFR1/2/3/4 Alterations

Enrollment Status: Active_not_recruiting

Publish Date: December 02, 2025

Intervention Type: Procedure, Other, Drug

Study Drug: Erdafitinib

Study Phase: Phase 2

A Safety, Pharmacokinetic and Efficacy Study of a y-Secretase Inhibitor, Nirogacestat (PF-03084014), in Children and Adolescents With Progressive, Surgically Unresectable Desmoid Tumors

Enrollment Status: Active_not_recruiting

Publish Date: December 02, 2025

Intervention Type: Other, Procedure, Drug

Study Drug: Nirogacestat

Study Phase: Phase 2

Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors

Enrollment Status: Active_not_recruiting

Publish Date: December 02, 2025

Intervention Type: Drug, Other

Study Drugs: Cabozantinib, Cabozantinib-S-Malate

Study Phase: Phase 2

A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)

Enrollment Status: Active_not_recruiting

Publish Date: December 01, 2025

Intervention Type: Drug, Radiation

Study Drugs: Bortezomib, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin, Doxorubicin, Etoposide, Hydrocortisone Sodium Succinate, Ifosfamide, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Thioguanine, Vincristine, Vincristine Sulfate

Study Phase: Phase 3

Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)

Enrollment Status: Active_not_recruiting

Publish Date: December 01, 2025

Intervention Type: Drug, Radiation, Procedure

Study Drugs: Doxorubicin, Ifosfamide, Pazopanib

Study Phase: Phase 2/Phase 3

Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma

Enrollment Status: Active_not_recruiting

Publish Date: December 01, 2025

Intervention Type: Drug, Procedure, Biological, Radiation

Study Drugs: Cyclophosphamide, Doxorubicin, Doxorubicin Hydrochloride, Etoposide, Etoposide Phosphate, Ganitumab, Ifosfamide, Vincristine, Vincristine Sulfate

Study Phase: Phase 3

Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)

Enrollment Status: Active_not_recruiting

Publish Date: December 01, 2025

Intervention Type: Drug, Procedure, Biological, Other, Radiation

Study Drugs: Asparaginase, Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Leucovorin Calcium, Mercaptopurine, Methotrexate, Mitoxantrone, Mitoxantrone Hydrochloride, Pegaspargase, Hydrocortisone, Thioguanine, Vincristine, Vincristine Sulfate

Study Phase: Phase 3

A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)

Enrollment Status: Active_not_recruiting

Publish Date: December 01, 2025

Intervention Type: Radiation, Drug, Biological, Other

Study Drugs: Cyclophosphamide, Dactinomycin, Irinotecan hydrochloride, Temsirolimus, Vincristine sulfate, Vinorelbine

Study Phase: Phase 3

A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults

Enrollment Status: Active_not_recruiting

Publish Date: December 01, 2025

Intervention Type: Other, Drug, Biological

Study Drugs: Bleomycin, Brentuximab, Cyclophosphamide, Doxorubicin, Etoposide, Methylprednisolone, Prednisone, Vincristine

Study Phase: Phase 3

A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations

Enrollment Status: Active_not_recruiting

Publish Date: November 26, 2025

Intervention Type: Drug, Other, Radiation

Study Drugs: Clofarabine, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Hydrocortisone Sodium Succinate, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Thioguanine, Vincristine Sulfate

Study Phase: Phase 3

A Phase III Randomized Trial for Patients With De Novo AML Using Bortezomib and Sorafenib (NSC# 681239, NSC# 724772) for Patients With High Allelic Ratio FLT3/ITD

Enrollment Status: Active_not_recruiting

Publish Date: November 26, 2025

Intervention Type: Other, Drug

Study Drugs: Asparaginase, Bortezomib, Cytarabine, Daunorubicin, Etoposide, Mitoxantrone, Sorafenib

Study Phase: Phase 3

Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment

Enrollment Status: Active_not_recruiting

Publish Date: November 25, 2025

Intervention Type: Drug, Other, Procedure

Study Drugs: Cisplatin, Dexrazoxane, Doxorubicin Hydrochloride, Fluorouracil, Irinotecan Hydrochloride, Temsirolimus, Vincristine Sulfate

Study Phase: Phase 3

Phase 2 Trial of Response-Based Radiation Therapy for Patients With Localized Central Nervous System Germ Cell Tumors (CNS GCT)

Enrollment Status: Completed

Publish Date: November 20, 2025

Intervention Type: Drug, Radiation

Study Phase: Phase 2

A Phase 2 Study of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG)

Enrollment Status: Active_not_recruiting

Publish Date: November 19, 2025

Intervention Type: Procedure, Radiation, Drug

Study Drugs: Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide

Study Phase: Phase 2

A Phase 3 Study of Selumetinib (NSC# 748727) or Selumetinib in Combination With Vinblastine for Non-NF1, Non-TSC Patients With Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations

Enrollment Status: Active_not_recruiting

Publish Date: November 19, 2025

Intervention Type: Other, Procedure, Drug

Study Drugs: Selumetinib, Vinblastine

Study Phase: Phase 3

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol

Enrollment Status: Active_not_recruiting

Publish Date: November 17, 2025

Intervention Type: Procedure, Drug, Other

Study Drugs: Ensartinib, Erdafitinib, Larotrectinib, Olaparib, Palbociclib, Samotolisib, Selpercatinib, Selumetinib Sulfate, Tazemetostat, Tipifarnib, Ulixertinib, Vemurafenib

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients With Tumors Harboring IDH1 Mutations

Enrollment Status: Active_not_recruiting

Publish Date: November 17, 2025

Intervention Type: Drug

Study Drug: Ivosidenib

Study Phase: Phase 2

A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)

Enrollment Status: Active_not_recruiting

Publish Date: November 17, 2025

Intervention Type: Other, Procedure, Drug

Study Drugs: Carboplatin, Selumetinib Sulfate, Vincristine Sulfate

Study Phase: Phase 3

A Phase I Study With an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients With Relapsed/Refractory Hodgkin Lymphoma

Enrollment Status: Active_not_recruiting

Publish Date: November 17, 2025

Intervention Type: Procedure, Drug, Biological

Study Drugs: Brentuximab, Ipilimumab, Nivolumab

Study Phase: Phase 1/Phase 2

A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

Enrollment Status: Active_not_recruiting

Publish Date: November 17, 2025

Intervention Type: Biological, Drug, Procedure, Radiation

Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide Phosphate, Filgrastim, Nivolumab, Pegfilgrastim, Prednisolone, Prednisone, Rituximab, Rituximab+Hyaluronidase Human, Vincristine Sulfate

Study Phase: Phase 3

A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)

Enrollment Status: Active_not_recruiting

Publish Date: November 17, 2025

Intervention Type: Drug, Biological, Radiation

Study Drugs: Erwinia Asparaginase, Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Prednisone, Thioguanine, Vincristine Sulfate

Study Phase: Phase 3

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations

Enrollment Status: Active_not_recruiting

Publish Date: November 17, 2025

Intervention Type: Procedure, Other, Drug

Study Drug: Ensartinib

Study Phase: Phase 2

A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600 Mutations

Enrollment Status: Active_not_recruiting

Publish Date: November 13, 2025

Intervention Type: Drug, Radiation

Study Drugs: Temozolomide, Veliparib

Study Phase: Phase 2

Neuroblastoma Biology Studies

Enrollment Status: Active_not_recruiting

Publish Date: November 13, 2025

Intervention Type: Other

A Phase 2 Study of the MEK Inhibitor Trametinib (NSC# 763093) in Children With Relapsed or Refractory Juvenile Myelomonocytic Leukemia

Enrollment Status: Active_not_recruiting

Publish Date: October 29, 2025

Intervention Type: Procedure, Drug

Study Drug: Trametinib

Study Phase: Phase 2

Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years

Enrollment Status: Active_not_recruiting

Publish Date: October 27, 2025

Intervention Type: Drug, Radiation, Biological, Other

Study Drugs: Carboplatin, Cisplatin, Cyclophosphamide, Etoposide, Vincristine

Study Phase: Phase 3

A Pilot Study of Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide in the Post-Consolidation Setting for High-Risk Neuroblastoma

Enrollment Status: Active_not_recruiting

Publish Date: October 27, 2025

Intervention Type: Procedure, Drug, Radiation, Biological

Study Drugs: Dinutuximab, Irinotecan, Isotretinoin, Sargramostim, Temozolomide

Study Phase: Phase 2

International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones

Enrollment Status: Active_not_recruiting

Publish Date: October 27, 2025

Intervention Type: Drug, Procedure, Other, Biological

Study Drugs: Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Dexrazoxane Hydrochloride, Doxorubicin, Etoposide, Filgrastim, Ifosfamide, Imatinib Mesylate, Leucovorin Calcium, Mercaptopurine, Methotrexate, Methylprednisolone, Pegaspargase, Prednisolone, Hydrocortisone, Thioguanine, Vincristine Sulfate

Study Phase: Phase 3

A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab With or Without Eflornithine (DFMO) in Children With Relapsed, Refractory or Progressive Neuroblastoma

Enrollment Status: Active_not_recruiting

Publish Date: October 27, 2025

Intervention Type: Drug, Biological

Study Drugs: Dinutuximab, Eflornithine Hydrochloride, Irinotecan Hydrochloride, Sargramostim, Temozolomide

Study Phase: Phase 2

A Phase II Trial of Tisagenlecleucel in First-line High-risk (HR) Pediatric and Young Adult Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL) Who Are Minimal Residual Disease (MRD) Positive at the End of Consolidation (EOC) Therapy

Enrollment Status: Active_not_recruiting

Publish Date: October 23, 2025

Intervention Type: Biological

Study Drug: CTL019

Study Phase: Phase 2

A Phase 3 Randomized, Placebo-Controlled Trial Evaluating Memantine for Neurocognitive Protection in Children Undergoing Cranial Radiotherapy as Part of Treatment for Primary Central Nervous System Tumors

Enrollment Status: Active_not_recruiting

Publish Date: October 14, 2025

Intervention Type: Procedure, Drug, Other

Study Drug: Memantine Hydrochloride

Study Phase: Phase 3

The Effectiveness of Lactobacillus Plantarum (LBP, IND# 17339) in Preventing Acute Graft-Versus-Host Disease (GvHD) in Children Undergoing Alternative Hematopoietic Progenitor Cell Transplantation (HCT)

Enrollment Status: Active_not_recruiting

Publish Date: October 06, 2025

Intervention Type: Procedure, Other, Biological

Study Drugs: Lactobacillus Plantarum Strain 299, Lactobacillus Plantarum Strain 299v

Study Phase: Phase 3

A Pivotal Phase 1/2, Single-Arm, Open-label Study to Evaluate the Safety and Efficacy of Ponatinib With Chemotherapy in Pediatric Patients With Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Who Have Relapsed or Are Resistant or Intolerant to a Prior Tyrosine Kinase Inhibitor-Containing Therapy, or Who Have the T315I Mutation

Enrollment Status: Terminated

Publish Date: October 02, 2025

Intervention Type: Drug

Study Drug: Ponatinib

Study Phase: Phase 1/Phase 2

A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Drug, Behavioral, Other, Procedure

Study Drug: 6-Mercaptopurine

Study Phase: Phase 3

Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children With Cancer

Enrollment Status: Active_not_recruiting

Publish Date: September 18, 2025

Intervention Type: Other, Procedure

Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)

Enrollment Status: Active_not_recruiting

Publish Date: September 02, 2025

Intervention Type: Drug, Other, Procedure

Study Drugs: Carboplatin, Cisplatin, Doxorubicin, Etoposide, Fluorouracil, Gemcitabine, Irinotecan, Oxaliplatin, Sorafenib, Vincristine Sulfate

Study Phase: Phase 3

A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients

Enrollment Status: Active_not_recruiting

Publish Date: August 12, 2025

Intervention Type: Drug, Procedure, Radiation, Other

Study Drugs: Cisplatin, Cyclophosphamide, Lomustine, Vincristine, Vincristine Sulfate

Study Phase: Phase 2

Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)

Enrollment Status: Active_not_recruiting

Publish Date: August 12, 2025

Intervention Type: Other, Procedure, Drug

Study Drug: Tyrosine Kinase Inhibitor

Study Phase: Phase 2

Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma

Enrollment Status: Active_not_recruiting

Publish Date: August 12, 2025

Intervention Type: Drug, Procedure, Other

Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide

Study Phase: Phase 3

Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome

Enrollment Status: Active_not_recruiting

Publish Date: August 01, 2025

Intervention Type: Drug, Other

Study Drugs: Asparaginase, Erwinia Asparaginase, Cytarabine, Daunorubicin, Etoposide, Mitoxantrone, Thioguanine

Study Phase: Phase 3

A Phase II Study of <131>I-Metaiodobenzyguanidine (<131>I-MIBG) Therapy for Patients With MIBG Avid Tumors

Enrollment Status: Active_not_recruiting

Publish Date: May 13, 2025

Intervention Type: Drug

Study Drug: MIBG

Study Phase: Phase 2

A Randomized Web-Based Physical Activity Intervention Among Children and Adolescents With Cancer

Enrollment Status: Active_not_recruiting

Publish Date: April 18, 2025

Intervention Type: Other, Device

Study Phase: Phase 3

Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)

Enrollment Status: Active_not_recruiting

Publish Date: April 01, 2025

Intervention Type: Other, Drug

Study Drugs: Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Thioguanine, Vincristine Sulfate

Study Phase: Phase 3

View 49 Less Clinical Trials

37 Total Publications

Wilms Tumor, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: August 05, 2025

View All 37 Publications

Similar Doctors

Elite in Ewing Sarcoma

Dr. Stephen L. Lessnick

Pediatric Hematology Oncology

Elite in Ewing Sarcoma

Dr. Stephen L. Lessnick

Pediatric Hematology Oncology

700 Childrens Dr,

Columbus, OH

(59.1 miles away)

614-722-4002

Languages Spoken:

English

See accepted insurances

Stephen Lessnick is a Pediatric Hematologist Oncology provider in Columbus, Ohio. Dr. Lessnick is rated as an Elite provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Ewing Sarcoma, Osteosarcoma, Adult Soft Tissue Sarcoma, and Infantile Neutropenia.

Distinguished in Ewing Sarcoma

Dr. Timothy P. Cripe

Pediatric Hematology Oncology

Distinguished in Ewing Sarcoma

Dr. Timothy P. Cripe

Pediatric Hematology Oncology

536 S Trimble Rd,

Mansfield, OH

(0.1 miles away)

614-722-6200

Languages Spoken:

English

See accepted insurances

Timothy Cripe is a Pediatric Hematologist Oncology provider in Mansfield, Ohio. Dr. Cripe is rated as a Distinguished provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Ewing Sarcoma, Embryonal Tumor with Multilayered Rosettes, Neuroblastoma, and Osteosarcoma.

Advanced in Ewing Sarcoma

Dr. Bhuvana A. Setty

Pediatric Hematology Oncology

Advanced in Ewing Sarcoma

Dr. Bhuvana A. Setty

Pediatric Hematology Oncology

740 Adair Ave,

Zanesville, OH

(61.6 miles away)

614-722-2000

Languages Spoken:

English

See accepted insurances

Bhuvana Setty is a Pediatric Hematologist Oncology provider in Zanesville, Ohio. Dr. Setty is rated as an Advanced provider by MediFind in the treatment of Ewing Sarcoma. Her top areas of expertise are Osteosarcoma, Adult Soft Tissue Sarcoma, Ewing Sarcoma, and Rhabdomyosarcoma.

VIEW MORE EWING SARCOMA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ranalli's expertise for a condition

ConditionClose

Distinguished
Neuroblastoma
Dr. Ranalli is
Distinguished
. Learn about Neuroblastoma.
See more Neuroblastoma experts

Advanced
Adult Soft Tissue Sarcoma
Dr. Ranalli is
Advanced
. Learn about Adult Soft Tissue Sarcoma.
See more Adult Soft Tissue Sarcoma experts
Denys-Drash Syndrome (DDS)
Dr. Ranalli is
Advanced
. Learn about Denys-Drash Syndrome (DDS).
See more Denys-Drash Syndrome (DDS) experts
Embryonal Tumor with Multilayered Rosettes
Dr. Ranalli is
Advanced
. Learn about Embryonal Tumor with Multilayered Rosettes.
See more Embryonal Tumor with Multilayered Rosettes experts
Ewing Sarcoma
Dr. Ranalli is
Advanced
. Learn about Ewing Sarcoma.
See more Ewing Sarcoma experts
Glioma
Dr. Ranalli is
Advanced
. Learn about Glioma.
See more Glioma experts
Hepatoblastoma
Dr. Ranalli is
Advanced
. Learn about Hepatoblastoma.
See more Hepatoblastoma experts

View All 15 Advanced Conditions

Experienced
Acute Lymphoblastic Leukemia (ALL)
Dr. Ranalli is
Experienced
. Learn about Acute Lymphoblastic Leukemia (ALL).
See more Acute Lymphoblastic Leukemia (ALL) experts
Bone Marrow Aspiration
Dr. Ranalli is
Experienced
. Learn about Bone Marrow Aspiration.
See more Bone Marrow Aspiration experts
Hepatic Venoocclusive Disease with Immunodeficiency
Dr. Ranalli is
Experienced
. Learn about Hepatic Venoocclusive Disease with Immunodeficiency.
See more Hepatic Venoocclusive Disease with Immunodeficiency experts
Hereditary Spherocytosis
Dr. Ranalli is
Experienced
. Learn about Hereditary Spherocytosis.
See more Hereditary Spherocytosis experts
Hodgkin Lymphoma
Dr. Ranalli is
Experienced
. Learn about Hodgkin Lymphoma.
See more Hodgkin Lymphoma experts
Infantile Neutropenia
Dr. Ranalli is
Experienced
. Learn about Infantile Neutropenia.
See more Infantile Neutropenia experts

View All 13 Experienced Conditions

Want to save this doctor for later?

Is this your doctor?

Find A Second Opinion

Not sure about your diagnosis?

Check Your Symptoms

Learn about our expert tiers

Learn More

Are you the provider on this profile?

Claim Profile